Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyNet Income towards Common StockholdersOperating ExpensesOperating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax RateTax Rate
Others
Ratios

Aligos Therapeutics (ALGS) Revenue (2021 - 2025)

Aligos Therapeutics filings provide 5 years of Revenue readings, the most recent being $169000.0 for Q4 2025.

  • On a quarterly basis, Revenue fell 94.88% to $169000.0 in Q4 2025 year-over-year; TTM through Dec 2025 was $2.2 million, a 65.33% decrease, with the full-year FY2025 number at $2.2 million, down 39.46% from a year prior.
  • Revenue hit $169000.0 in Q4 2025 for Aligos Therapeutics, down from $741000.0 in the prior quarter.
  • In the past five years, Revenue ranged from a high of $13.9 million in Q4 2022 to a low of $140000.0 in Q1 2023.
  • Median Revenue over the past 5 years was $1.2 million (2024), compared with a mean of $2.1 million.
  • Biggest five-year swings in Revenue: soared 3689.37% in 2022 and later crashed 94.88% in 2025.
  • Aligos Therapeutics' Revenue stood at $367000.0 in 2021, then soared by 3689.37% to $13.9 million in 2022, then plummeted by 85.55% to $2.0 million in 2023, then soared by 64.26% to $3.3 million in 2024, then crashed by 94.88% to $169000.0 in 2025.
  • The last three reported values for Revenue were $169000.0 (Q4 2025), $741000.0 (Q3 2025), and $965000.0 (Q2 2025) per Business Quant data.